Bayer shares climbed sharply in European trading after the US Supreme Court issued a ruling in favor of the German chemical giant in its long-running legal battle over cancer risks linked to its Roundup herbicide.
The decision marks a decisive turning point in a dispute that has loomed over the company’s balance sheet for years, with investors quickly rewarding the reduced legal uncertainty.
The market reaction was immediate and pronounced, with Bayer’s stock jumping on the news.
The price move reflects a significant de-risking of the company’s US litigation exposure, which had previously weighed heavily on investor sentiment and valuation multiples.
Traders appear to be repricing the equity based on the expectation that this Supreme Court intervention will limit future liability and streamline the resolution of remaining claims.
This development follows a period of intense legal scrutiny for Bayer, which acquired Monsanto in 2018 and inherited thousands of lawsuits alleging that glyphosate causes non-Hodgkin lymphoma.